{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T10:27:16Z","timestamp":1764325636048,"version":"3.46.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP25fk0210126, JP25fk0310545, JP24fk0210121, JP25fk0210142, JP25fk0310551, JP25fk0210123, JP25fk0310535, JP25fk0210157, JP25fk0310543, JP25fk0210172 JP25fk0210174, JP25fk0210143"],"award-info":[{"award-number":["JP25fk0210126, JP25fk0310545, JP24fk0210121, JP25fk0210142, JP25fk0310551, JP25fk0210123, JP25fk0310535, JP25fk0210157, JP25fk0310543, JP25fk0210172 JP25fk0210174, JP25fk0210143"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017784","name":"Gilead Research Scholars","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017784","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-26891-4","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T10:23:54Z","timestamp":1764325434000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Simplified monitoring of sofosbuvir\/velpatasvir in Japanese patients with chronic hepatitis C based on a retrospective analysis of a prospective multicenter cohort"],"prefix":"10.1038","volume":"15","author":[{"given":"Goki","family":"Suda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Baba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiya","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonoe","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuhito","family":"Muranaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Meguro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsumi","family":"Terashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoe","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomofumi","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunichi","family":"Hosoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingjie","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zijian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takatsugu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akimitsu","family":"Meno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohiro","family":"Yasuura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kitagataya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatsugu","family":"Ohara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Kawagishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Sho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoya","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"26891_CR1","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41575-022-00608-8","volume":"19","author":"MP Manns","year":"2022","unstructured":"Manns, M. P. & Maasoumy, B. Breakthroughs in hepatitis C research: from discovery to cure. Nat. Rev. Gastroenterol. Hepatol. 19, 533\u2013550. https:\/\/doi.org\/10.1038\/s41575-022-00608-8 (2022).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"26891_CR2","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00535-018-1503-x","volume":"54","author":"T Takehara","year":"2019","unstructured":"Takehara, T. et al. Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial. J. Gastroenterol. 54, 87\u201395. https:\/\/doi.org\/10.1007\/s00535-018-1503-x (2019).","journal-title":"J. Gastroenterol."},{"key":"26891_CR3","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s00535-017-1427-x","volume":"53","author":"G Suda","year":"2018","unstructured":"Suda, G., Ogawa, K., Morikawa, K. & Sakamoto, N. Treatment of hepatitis C in special populations. J. Gastroenterol. 53, 591\u2013605. https:\/\/doi.org\/10.1007\/s00535-017-1427-x (2018).","journal-title":"J. Gastroenterol."},{"key":"26891_CR4","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00535-017-1353-y","volume":"53","author":"G Suda","year":"2018","unstructured":"Suda, G. et al. Daclatasvir and asunaprevir in Hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan. J. Gastroenterol. 53, 119\u2013128. https:\/\/doi.org\/10.1007\/s00535-017-1353-y (2018).","journal-title":"J. Gastroenterol."},{"key":"26891_CR5","doi-asserted-by":"publisher","first-page":"943","DOI":"10.2169\/internalmedicine.2077-18","volume":"58","author":"G Suda","year":"2019","unstructured":"Suda, G. et al. The successful retreatment with glecaprevir and Pibrentasvir of genotype 1 or 2 HCV-infected Hemodialysis patients who failed to respond to NS5A and protease inhibitor treatment. Intern. Med. 58, 943\u2013947. https:\/\/doi.org\/10.2169\/internalmedicine.2077-18 (2019).","journal-title":"Intern. Med."},{"key":"26891_CR6","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.jhep.2019.10.010","volume":"72","author":"GJ Dore","year":"2020","unstructured":"Dore, G. J. et al. Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. J. Hepatol. 72, 431\u2013440. https:\/\/doi.org\/10.1016\/j.jhep.2019.10.010 (2020).","journal-title":"J. Hepatol."},{"key":"26891_CR7","doi-asserted-by":"publisher","unstructured":"Yang, A., Swamy, N. & Giang, J. Single-center retrospective review of standard versus minimal monitoring for hepatitis C direct-acting antiviral therapy. J. Am. Pharm. Assoc. 65 (102265). https:\/\/doi.org\/10.1016\/j.japh.2024.102265. (2025).","DOI":"10.1016\/j.japh.2024.102265"},{"key":"26891_CR8","doi-asserted-by":"publisher","first-page":"100428","DOI":"10.1016\/j.lanwpc.2022.100428","volume":"22","author":"J Tanaka","year":"2022","unstructured":"Tanaka, J. et al. Burden of chronic hepatitis B and C infections in 2015 and future trends in japan: A simulation study. Lancet Reg. Health West. Pac. 22, 100428. https:\/\/doi.org\/10.1016\/j.lanwpc.2022.100428 (2022).","journal-title":"Lancet Reg. Health West. Pac."},{"key":"26891_CR9","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","volume":"373","author":"GR Foster","year":"2015","unstructured":"Foster, G. R. et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl. J. Med. 373, 2608\u20132617. https:\/\/doi.org\/10.1056\/NEJMoa1512612 (2015).","journal-title":"N Engl. J. Med."},{"key":"26891_CR10","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1053\/j.gastro.2016.07.038","volume":"151","author":"EJ Gane","year":"2016","unstructured":"Gane, E. J. et al. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in patients with hepatitis C virus genotype 2, 3, 4, or 6 infections in an Open-Label, phase 2 trial. Gastroenterology 151, 902\u2013909. https:\/\/doi.org\/10.1053\/j.gastro.2016.07.038 (2016).","journal-title":"Gastroenterology"},{"key":"26891_CR11","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","volume":"373","author":"JJ Feld","year":"2015","unstructured":"Feld, J. J. et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl. J. Med. 373, 2599\u20132607. https:\/\/doi.org\/10.1056\/NEJMoa1512610 (2015).","journal-title":"N Engl. J. Med."},{"key":"26891_CR12","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1111\/hepr.13810","volume":"52","author":"T Takehara","year":"2022","unstructured":"Takehara, T. et al. Sofosbuvir-velpatasvir in adults with hepatitis C virus infection and compensated cirrhosis in Japan. Hepatol. Res. 52, 833\u2013840. https:\/\/doi.org\/10.1111\/hepr.13810 (2022).","journal-title":"Hepatol. Res."},{"key":"26891_CR13","doi-asserted-by":"publisher","first-page":"101364","DOI":"10.1016\/j.jhepr.2025.101364","volume":"7","author":"R Kohya","year":"2025","unstructured":"Kohya, R. et al. Serum FGF21 as a predictor of response to Atezolizumab and bevacizumab in HCC. JHEP Rep. 7, 101364. https:\/\/doi.org\/10.1016\/j.jhepr.2025.101364 (2025).","journal-title":"JHEP Rep."},{"key":"26891_CR14","doi-asserted-by":"publisher","first-page":"e28452","DOI":"10.1002\/jmv.28452","volume":"95","author":"G Suda","year":"2023","unstructured":"Suda, G. et al. Prophylactic Tenofovir Alafenamide for hepatitis B virus reactivation and reactivation-related hepatitis. J. Med. Virol. 95, e28452. https:\/\/doi.org\/10.1002\/jmv.28452 (2023).","journal-title":"J. Med. Virol."},{"key":"26891_CR15","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00535-016-1162-8","volume":"51","author":"G Suda","year":"2016","unstructured":"Suda, G. et al. Efficacy and safety of Daclatasvir and asunaprevir combination therapy in chronic Hemodialysis patients with chronic hepatitis C. J. Gastroenterol. 51, 733\u2013740. https:\/\/doi.org\/10.1007\/s00535-016-1162-8 (2016).","journal-title":"J. Gastroenterol."},{"key":"26891_CR16","doi-asserted-by":"publisher","unstructured":"Suda, G. et al. Long non-coding RNA PWRN4 associated with post-SVR hepatocellular carcinoma: a genome-wide association study. Biomark. Res. 13 https:\/\/doi.org\/10.1186\/s40364-025-00832-9 (2025).","DOI":"10.1186\/s40364-025-00832-9"},{"key":"26891_CR17","doi-asserted-by":"publisher","unstructured":"Kawagishi, N. et al. Serum Angiopoietin-2 Predicts the Occurrence and Recurrence of Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy for Hepatitis C. Viruses 15. https:\/\/doi.org\/10.3390\/v15010181 (2023).","DOI":"10.3390\/v15010181"},{"key":"26891_CR18","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S2468-1253(21)00397-6","volume":"7","author":"SS Solomon","year":"2022","unstructured":"Solomon, S. S. et al. A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial. Lancet Gastroenterol. Hepatol. 7, 307\u2013317. https:\/\/doi.org\/10.1016\/S2468-1253(21)00397-6 (2022).","journal-title":"Lancet Gastroenterol. Hepatol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26891-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26891-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26891-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T10:24:05Z","timestamp":1764325445000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26891-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["26891"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-26891-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"19 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Professor Naoya Sakamoto received lecture fees from Chugai Pharmaceutical Co., Ltd, Gilead Sciences, Inc. and AbbVie Inc, grants and endowments from MSD K.K and Chugai Pharmaceutical Co., Ltd, and a research grant from AbbVie Inc. Dr. Goki Suda received research grants from Gilead Sciences. The other authors have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42628"}}